Anzeige
Mehr »
Login
Montag, 17.05.2021 Börsentäglich über 12.000 News von 658 internationalen Medien
Suchen Sie auch nach Fosterville South (A2QJKK)? Hier gibt´s News!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PT5P ISIN: US24661P8077 Ticker-Symbol: DV3R 
Stuttgart
17.05.21
08:09 Uhr
8,300 Euro
0,000
0,00 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
DELCATH SYSTEMS INC Chart 1 Jahr
5-Tage-Chart
DELCATH SYSTEMS INC 5-Tage-Chart

Aktuelle News zur DELCATH SYSTEMS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiDelcath Systems ticks up despite missed Q1 projections1
DiDELCATH SYSTEMS, INC. - 10-Q, Quaterly Report1
DELCATH SYSTEMS Aktie jetzt für 0€ handeln
DiDelcath Systems: Q1 Earnings Insights-
DiDelcath Systems Slips To Loss In Q1197WASHINGTON (dpa-AFX) - Delcath Systems Inc. (DCTH) reported that its first-quarter net loss was $6.8 million or $1.04 per share, compared to a net income of $7.9 million last year.Total operating...
► Artikel lesen
DiDelcath Systems EPS misses by $0.06, revenue in-line1
21.04.Delcath Systems, Inc. Announces Revised NICE Guidance for CHEMOSAT in the United Kingdom1
01.04.DELCATH SYSTEMS, INC. - 8-K, Current Report2
31.03.Delcath Systems, Inc. 2020 Q4 - Results - Earnings Call Presentation2
31.03.Delcath Systems, Inc. Shares Additional Information Regarding FOCUS Trial Power Calculation-
31.03.Delcath Systems, Inc. (DCTH) CEO Gerard Michel on Q4 2020 Results - Earnings Call Transcript-
31.03.Delcath Systems (DCTH) Presents Trial Preliminary Data - Slideshow-
31.03.DELCATH SYSTEMS, INC. - 10-K, Annual Report3
31.03.Greenlane, SunLink Health Systems leads healthcare gainers; 9 Meters Biopharma, Delcath Systems among major losers9
31.03.Recap: Delcath Systems Q4 Earnings1
31.03.Delcath Systems Reports Positive Preliminary Results From Phase 3 FOCUS Trial Of HEPZATO265WASHINGTON (dpa-AFX) - Delcath Systems, Inc. (DCTH) reported positive top-line preliminary results from the phase 3 FOCUS trial of HEPZATO KIT in patients with liver dominant metastatic ocular...
► Artikel lesen
31.03.Delcath Stock Moves Higher After Hepzato Achieves ORR Of 29.2% Beating Prespecified Threshold In Eye Cancer Study2
31.03.Delcath Systems misses on revenue1
31.03.Delcath Systems, Inc. Announces Fourth Quarter 2020 Results, Highlights Preliminary Positive FOCUS Trial Results; Conference Call Today at 8:00am Eastern ...3
31.03.Delcath Systems, Inc. Announces Positive Preliminary Results from Phase 3 FOCUS Trial of HEPZATO in Patients with Metastatic Ocular Melanoma2
24.03.Delcath Systems, Inc.: Delcath Systems Schedules Conference Call to Report 2020 Fourth Quarter Financial Results1
Seite:  Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1